Where Your News Is Made.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is October 20, 2018.
All times in Eastern Daylight Time.
-
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentri... more » -
Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant ... more » -
Medical Society of the District of Columbia Honors Neal Barnard, M.D., F.A.C.C.
WASHINGTON--(BUSINESS WIRE)--The Medical Society of the District of Columbia (MSDC) will present Neal Barnard, M.D., F.A.C.C., its Distinguished Service Award at MSDC’s 201st Annual Meeting and Rec... more » -
Infiniti Research Reveals Five Promising Trends Emerging in the Food Packaging Market
LONDON--(BUSINESS WIRE)--Trends emerging in the food packaging market. more » -
Quantzig Reveals the Challenges Hindering the Adoption of Blockchain in Healthcare
LONDON--(BUSINESS WIRE)--The challenges hindering the adoption of blockchain in healthcare. more » -
Quantzig Predicts the Future of Bitcoin - Proclaims It a Gamble
LONDON--(BUSINESS WIRE)--The future of bitcoin. more » -
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
KENILWORTH, N.J.--(BUSINESS WIRE)--First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 more » -
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibito... more » -
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 CongressWALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and ... more »
-
Takeda apresenta resultados do ensaio ALTA-1L de fase 3 que destaca a eficácia intracraniana do ALUNBRIG® (brigatinibe) em relação ao crizotinibe no câncer de pulmão de não pequenas células ALK+ avançado de primeira linha
CAMBRIDGE, Massachusetts e OSAKA, Japão--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) anunciou hoje que os dados de eficácia intracraniana do ensaio Fase 3 ALTA-1L (sigla para... more » -
C5 Capital to Sign Landmark Atlantic Future Forum Accord on Cyber Security and Artificial IntelligenceLONDON--(BUSINESS WIRE)--C5 Capital Limited (“C5”), the specialist venture capital firm focused on investing in cloud computing, cyber and artificial intelligence, announces managing partner and fo... more »
-
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer more » -
Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck’s KEYTRUDA Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk NMIBC Unresponsive to Standard of Care more » -
Manchester United et True Religion lancent une gamme de vêtements en denim
LOS ANGELES--(BUSINESS WIRE)--Manchester United (NYSE : MANU) et la marque de luxe de denim, True Religion, ont collaboré pour lancer une gamme de vêtements à l’effigie du club, en denim de qualité... more »
-
Manchester United e True Religion lançam coleção de denim
LOS ANGELES--(BUSINESS WIRE)--O Manchester United (NYSE: MANU) e a marca de denim de luxo True Religion realizaram uma colaboração para lançar uma coleção premium de roupa denim com a marca do club... more »